International Consortium on Meningiomas (ICOM)
@icomeningioma.bsky.social
ICOM, under the leadership of Dr. Gelareh Zadeh, increases awareness and conducts high quality cutting-edge research on meningiomas.
Dr. Jackson is a #SkullBase #neurosurgeon-scientist @PennNSG specializing in open and endoscopic approaches for complex brain and skull base tumors. Her research focuses on developing novel immune-based therapies for #meningioma and other skull base tumors.
November 26, 2025 at 11:05 AM
Dr. Jackson is a #SkullBase #neurosurgeon-scientist @PennNSG specializing in open and endoscopic approaches for complex brain and skull base tumors. Her research focuses on developing novel immune-based therapies for #meningioma and other skull base tumors.
Read the new #ICOM collaboration paper in #NeuroOncology which provides a data-driven approach for integrating prediction models for personalized #meningioma care:
bit.ly/49A15Jj
@gelarehzadeh.bsky.social
bit.ly/49A15Jj
@gelarehzadeh.bsky.social
November 24, 2025 at 11:11 AM
Read the new #ICOM collaboration paper in #NeuroOncology which provides a data-driven approach for integrating prediction models for personalized #meningioma care:
bit.ly/49A15Jj
@gelarehzadeh.bsky.social
bit.ly/49A15Jj
@gelarehzadeh.bsky.social
Reposted by International Consortium on Meningiomas (ICOM)
Great to see the results of the IMPACt study out! Data for 1248 patients were used to validate our tool for stratifying incidental #meningioma management. Thanks to our collaborators across participating centres. Prospective implementation next @icomeningioma.bsky.social
The IMPACT tool accurately stratifies incidental meningioma patients by progression risk, supporting early intervention for high-risk, monitoring for medium-risk, and safe discharge for low-risk individuals. ja.ma/49xigv4
November 21, 2025 at 6:31 PM
Great to see the results of the IMPACt study out! Data for 1248 patients were used to validate our tool for stratifying incidental #meningioma management. Thanks to our collaborators across participating centres. Prospective implementation next @icomeningioma.bsky.social
“The Evolving Role of #TERT Alterations in #Meningioma Risk Stratification” by Sybren L N Maas, Arie Perry, and Felix Sahm is now available as an accepted manuscript in #NeuroOncology.
Read it here: bit.ly/47D2Hj3
Read it here: bit.ly/47D2Hj3
November 21, 2025 at 12:33 PM
“The Evolving Role of #TERT Alterations in #Meningioma Risk Stratification” by Sybren L N Maas, Arie Perry, and Felix Sahm is now available as an accepted manuscript in #NeuroOncology.
Read it here: bit.ly/47D2Hj3
Read it here: bit.ly/47D2Hj3
Reposted by International Consortium on Meningiomas (ICOM)
Can DNA methylation risk groups unlock personalized radiotherapy decisions in meningioma? Our new paper provides the clinical framework — thanks to all collaborators! @neuroonc.bsky.social @eanoassociation.bsky.social @gelarehzadeh.bsky.social @icomeningioma.bsky.social
doi.org/10.1093/neuo...
doi.org/10.1093/neuo...
A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma
AbstractBackground. DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patien
doi.org
November 20, 2025 at 9:29 AM
Can DNA methylation risk groups unlock personalized radiotherapy decisions in meningioma? Our new paper provides the clinical framework — thanks to all collaborators! @neuroonc.bsky.social @eanoassociation.bsky.social @gelarehzadeh.bsky.social @icomeningioma.bsky.social
doi.org/10.1093/neuo...
doi.org/10.1093/neuo...
Reminder to everyone attending #SNO - we will be holding the #ICOM Meningioma Meeting on Friday. All are welcome!
⏱️ 5:00-6:30pm
📍 Room Manoa 304AB, Hawai'i Convention Center
ℹ️ Presenting cutting edge #meningioma research and an opportunity to establish new collaborations
⏱️ 5:00-6:30pm
📍 Room Manoa 304AB, Hawai'i Convention Center
ℹ️ Presenting cutting edge #meningioma research and an opportunity to establish new collaborations
November 19, 2025 at 9:55 PM
Reminder to everyone attending #SNO - we will be holding the #ICOM Meningioma Meeting on Friday. All are welcome!
⏱️ 5:00-6:30pm
📍 Room Manoa 304AB, Hawai'i Convention Center
ℹ️ Presenting cutting edge #meningioma research and an opportunity to establish new collaborations
⏱️ 5:00-6:30pm
📍 Room Manoa 304AB, Hawai'i Convention Center
ℹ️ Presenting cutting edge #meningioma research and an opportunity to establish new collaborations
Two more weeks until the abstract submission deadline for #ICOM education day at the #NASBS Annual Meeting.
This program is organized independently by ICOM and will be held as a non-CME session in partnership with NASBS.
Find out more information here: bit.ly/43YyJ7V
This program is organized independently by ICOM and will be held as a non-CME session in partnership with NASBS.
Find out more information here: bit.ly/43YyJ7V
November 17, 2025 at 10:54 AM
Two more weeks until the abstract submission deadline for #ICOM education day at the #NASBS Annual Meeting.
This program is organized independently by ICOM and will be held as a non-CME session in partnership with NASBS.
Find out more information here: bit.ly/43YyJ7V
This program is organized independently by ICOM and will be held as a non-CME session in partnership with NASBS.
Find out more information here: bit.ly/43YyJ7V
The Brain Tumour Charity has just announced Quest for Cures funding for projects including targeting #meningioma through immune interactions led by @gelarehzadeh.bsky.social!
bit.ly/485CGdl
@braintumourcharity.bsky.social
bit.ly/485CGdl
@braintumourcharity.bsky.social
November 14, 2025 at 10:57 AM
The Brain Tumour Charity has just announced Quest for Cures funding for projects including targeting #meningioma through immune interactions led by @gelarehzadeh.bsky.social!
bit.ly/485CGdl
@braintumourcharity.bsky.social
bit.ly/485CGdl
@braintumourcharity.bsky.social
Submit your abstract for ICOM education day at the #NASBS Annual Meeting by Dec 1!
We invite submissions from professionals in the #SkullBase & #neurosurgical communities to share innovative research, clinical experience, or technical advancements.
bit.ly/43YyJ7V
We invite submissions from professionals in the #SkullBase & #neurosurgical communities to share innovative research, clinical experience, or technical advancements.
bit.ly/43YyJ7V
November 11, 2025 at 11:20 AM
Submit your abstract for ICOM education day at the #NASBS Annual Meeting by Dec 1!
We invite submissions from professionals in the #SkullBase & #neurosurgical communities to share innovative research, clinical experience, or technical advancements.
bit.ly/43YyJ7V
We invite submissions from professionals in the #SkullBase & #neurosurgical communities to share innovative research, clinical experience, or technical advancements.
bit.ly/43YyJ7V
Join us next week for the #ICOM #Meningioma Meeting at SNO in Honolulu!
At this meeting, we will be presenting cutting edge meningioma research and an opportunity to establish new collaborations and expand and advance ICOM. All are welcome.
At this meeting, we will be presenting cutting edge meningioma research and an opportunity to establish new collaborations and expand and advance ICOM. All are welcome.
November 10, 2025 at 11:34 AM
Join us next week for the #ICOM #Meningioma Meeting at SNO in Honolulu!
At this meeting, we will be presenting cutting edge meningioma research and an opportunity to establish new collaborations and expand and advance ICOM. All are welcome.
At this meeting, we will be presenting cutting edge meningioma research and an opportunity to establish new collaborations and expand and advance ICOM. All are welcome.
RTOG Foundation recently opened a new trial RTOG 3523, also known as the “MOMENTUM-1” study, testing the radioactive drug [177Lu]Lu-DOTA-TATE in adult who have progressive intracranial grade 1-3 #meningioma.
Read about the exciting new trial here: bit.ly/3LKevZd
Read about the exciting new trial here: bit.ly/3LKevZd
![Press release: RTOG Foundation Opens New Study Testing [177Lu]Lu-DOTA-TATE for Adults with Meningioma](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:svyki2fewnxvjjqihnbxzsj7/bafkreicbphxvlreq37uhdfyp3ygrotoo66mb3gg3qfssefaezzix56dbcu@jpeg)
November 5, 2025 at 11:19 AM
RTOG Foundation recently opened a new trial RTOG 3523, also known as the “MOMENTUM-1” study, testing the radioactive drug [177Lu]Lu-DOTA-TATE in adult who have progressive intracranial grade 1-3 #meningioma.
Read about the exciting new trial here: bit.ly/3LKevZd
Read about the exciting new trial here: bit.ly/3LKevZd
Join us at the SNO meetings in Honolulu on November 21st for the #ICOM #Meningioma Meeting!
We will be presenting cutting edge meningioma research and an opportunity to establish new collaborations and expand and advance ICOM. All are welcome.
We will be presenting cutting edge meningioma research and an opportunity to establish new collaborations and expand and advance ICOM. All are welcome.
November 3, 2025 at 11:20 AM
Join us at the SNO meetings in Honolulu on November 21st for the #ICOM #Meningioma Meeting!
We will be presenting cutting edge meningioma research and an opportunity to establish new collaborations and expand and advance ICOM. All are welcome.
We will be presenting cutting edge meningioma research and an opportunity to establish new collaborations and expand and advance ICOM. All are welcome.
Reposted by International Consortium on Meningiomas (ICOM)
🎗️ EANO proudly supports the 2025 International Brain Tumour Awareness Week! Let’s raise awareness, support patients, and promote advancements in research in #NeuroOncology. Together, we can make a difference!
#EANO #BrainTumourAwareness #btsm #BrainTumours
#EANO #BrainTumourAwareness #btsm #BrainTumours
October 28, 2025 at 1:00 PM
🎗️ EANO proudly supports the 2025 International Brain Tumour Awareness Week! Let’s raise awareness, support patients, and promote advancements in research in #NeuroOncology. Together, we can make a difference!
#EANO #BrainTumourAwareness #btsm #BrainTumours
#EANO #BrainTumourAwareness #btsm #BrainTumours
“Long-Term Outcomes of Active Surveillance After DOTATATE PET/MRI–Confirmed Gross Total Resection in WHO Grade 2 #Meningioma” is now available in NOA as an accepted manuscript:
academic.oup.com/noa/advance-...
academic.oup.com/noa/advance-...
October 31, 2025 at 11:35 AM
“Long-Term Outcomes of Active Surveillance After DOTATATE PET/MRI–Confirmed Gross Total Resection in WHO Grade 2 #Meningioma” is now available in NOA as an accepted manuscript:
academic.oup.com/noa/advance-...
academic.oup.com/noa/advance-...
Read the oral abstract poster from August aiming to identify chromosomal copy number alterations which could be used to improve the current CNS WHO grading of meningioma.
Read more in @EditorNeuro: bit.ly/4ng5d4m
Read more in @EditorNeuro: bit.ly/4ng5d4m
October 24, 2025 at 10:51 AM
Read the oral abstract poster from August aiming to identify chromosomal copy number alterations which could be used to improve the current CNS WHO grading of meningioma.
Read more in @EditorNeuro: bit.ly/4ng5d4m
Read more in @EditorNeuro: bit.ly/4ng5d4m
Read the letter to the editor ‘PAS+/PASD- intracytoplasmic glycogen is not specific for clear cell #meningioma’ published in the Journal of #Neuropathology & Experimental #Neurology:
bit.ly/4986hUr
bit.ly/4986hUr
October 22, 2025 at 10:27 AM
Read the letter to the editor ‘PAS+/PASD- intracytoplasmic glycogen is not specific for clear cell #meningioma’ published in the Journal of #Neuropathology & Experimental #Neurology:
bit.ly/4986hUr
bit.ly/4986hUr
Read about the first study to comprehensively define the molecular landscape of #meningiomas treated with #Radiotherapy in a prospective clinical trial in #NeuroOncology Advances:
bit.ly/4okYUNK
bit.ly/4okYUNK
October 20, 2025 at 10:50 AM
Read about the first study to comprehensively define the molecular landscape of #meningiomas treated with #Radiotherapy in a prospective clinical trial in #NeuroOncology Advances:
bit.ly/4okYUNK
bit.ly/4okYUNK
This recent article found that #mesothelin is a viable CAR T-cell target for #meningiomas, and mesothelin-specific CAR T-cell therapy shows strong preclinical efficacy.
Read more in #NeuroOncology:
bit.ly/43bm94Q
Read more in #NeuroOncology:
bit.ly/43bm94Q
October 17, 2025 at 10:23 AM
This recent article found that #mesothelin is a viable CAR T-cell target for #meningiomas, and mesothelin-specific CAR T-cell therapy shows strong preclinical efficacy.
Read more in #NeuroOncology:
bit.ly/43bm94Q
Read more in #NeuroOncology:
bit.ly/43bm94Q
Read the poster presentation in #NeuroOncology around a new study showing that preoperative #PET imaging may significantly adjust and extend resection boundaries in #meningiomas, particularly in cases of skull base and #IntraosseousMeningiomas.
bit.ly/3IIgVqr
bit.ly/3IIgVqr
October 15, 2025 at 10:34 AM
Read the poster presentation in #NeuroOncology around a new study showing that preoperative #PET imaging may significantly adjust and extend resection boundaries in #meningiomas, particularly in cases of skull base and #IntraosseousMeningiomas.
bit.ly/3IIgVqr
bit.ly/3IIgVqr
An older but insightful article by some #ICOM members, highlighting diagnostic challenges of #meningiomas from the #neuroimaging and #neuropathological side, presenting scientific achievements & studies potentially helping in overcoming these challenges:
academic.oup.com/neuro-oncolo...
academic.oup.com/neuro-oncolo...
October 13, 2025 at 5:42 PM
An older but insightful article by some #ICOM members, highlighting diagnostic challenges of #meningiomas from the #neuroimaging and #neuropathological side, presenting scientific achievements & studies potentially helping in overcoming these challenges:
academic.oup.com/neuro-oncolo...
academic.oup.com/neuro-oncolo...
“Understanding the role of the Hippo signalling pathway in ependymoma tumour biology” is available in the first volume of the new #NeuroOncology #Pediatrics:
bit.ly/471UhkK
bit.ly/471UhkK
October 10, 2025 at 10:45 AM
“Understanding the role of the Hippo signalling pathway in ependymoma tumour biology” is available in the first volume of the new #NeuroOncology #Pediatrics:
bit.ly/471UhkK
bit.ly/471UhkK
Read the systematic review and meta-analysis which evaluates the effect of #GammaKnife #radiosurgery dose-rate on managing intracranial targets, encompassing an assessment of its association with radiation-related toxicity and adverse effects.
bit.ly/3Kt8UWJ
bit.ly/3Kt8UWJ
October 8, 2025 at 10:33 AM
Read the systematic review and meta-analysis which evaluates the effect of #GammaKnife #radiosurgery dose-rate on managing intracranial targets, encompassing an assessment of its association with radiation-related toxicity and adverse effects.
bit.ly/3Kt8UWJ
bit.ly/3Kt8UWJ
A new article in @BrainTumourOrg highlights the findings from the Lancet Oncology paper ‘Analysis of TERT association with clinical outcome in #meningiomas: a multi-institutional cohort study’
bit.ly/46CpXhN
bit.ly/46CpXhN
October 6, 2025 at 11:03 AM
A new article in @BrainTumourOrg highlights the findings from the Lancet Oncology paper ‘Analysis of TERT association with clinical outcome in #meningiomas: a multi-institutional cohort study’
bit.ly/46CpXhN
bit.ly/46CpXhN